Mechanism of SSRIs: Monoamine Theory and the Role of BDNF

Summary

This video delves into the intricate mechanisms of selective serotonin reuptake inhibitors (SSRIs), providing an overview of the monoamine theory of depression and discussing its limitations. The presentation is divided into three main sections. Firstly, it critiques the classical monoamine theory, emphasizing the delay in antidepressant effects despite immediate molecular actions. Secondly, it explores how downregulation of 5HT1A receptors might explain these delayed therapeutic effects, showcasing the role of these receptors as inhibitory autoreceptors that are eventually downregulated in response to increased serotonin concentration. Finally, the video examines the role of brain-derived neurotrophic factor (BDNF) in depression, highlighting recent findings that associate BDNF with antidepressant responses and improvements in neuronal plasticity.

Highlights

• SSRIs have an immediate molecular impact, but the clinical effects take weeks to manifest. 🕒
• 5HT1A receptor downregulation is like taking the foot off the brake pedal, allowing neurons to fire more. 🚀
• BDNF levels are crucial for neural plasticity and depression recovery! 🌿
• Not all of depression is due to low serotonin — it's a complex biochemical dance. 🎶
• New insights into BDNF suggest a critical role in antidepressant efficacy and neuronal health. 🧬

Key Takeaways

• SSRI action isn't as immediate as it seems; therapeutic effects take a while to kick in! 🕒
• 5HT1A receptor downregulation might be the key to understanding delayed effects of SSRIs. 🧠
• BDNF plays a crucial role in fighting depression through enhancing neuronal plasticity. 🌱
• The monoamine theory of depression has its limitations — it's not all about serotonin levels. ⚖️
• Recent studies put the spotlight on BDNF's role in neural health and mood enhancement. 💡

Overview

Selective Serotonin Reuptake Inhibitors (SSRIs) have long been heralded in the treatment of depression, yet their precise actions have sparked much debate. While these medications immediately block serotonin reuptake at the molecular level, clinical relief often lags by weeks, raising questions about the initial monoamine theory of depression. This theory once suggested that depression was simply a matter of low serotonin and norepinephrine levels, but real-world observations tell a more complex story.

Enter the 5HT1A receptors! Acting as safety brakes within the brain's serotonin highways, these receptors have an inhibitory effect on serotonin release. When SSRIs increase serotonin levels, the 5HT1A receptors downregulate over time, lifting these brakes and increasing neuronal firing rates, effectively doubling down on serotonin activity. This gradual biochemical ballet might just explain the time lag in developing full antidepressant effects.

But there's more to the brain's recovery story. The role of Brain-Derived Neurotrophic Factor (BDNF) in depression uncovers a new layer of understanding. BDNF, a protein that supports neuron growth and function, may contribute significantly to the mood-lifting effects of antidepressants. Studies reveal that its levels often dip in depression but rise with successful SSRI therapy, showcasing its potential in enhancing neuronal plasticity and mood recovery.

Chapters

• 00:00 - 00:30: Monoamine Theory of Depression The chapter provides an overview of the Monoamine Theory of Depression. It is structured into three sections: the first section gives a brief overview of the Monoamine Theory of Depression and its limitations, the second section discusses the effects of 5-HT1A receptor downregulation on the mechanism of action of selective serotonin reuptake inhibitors (SSRIs), and the third section presents additional details not provided in the transcript.
• 00:30 - 05:00: Role of 5-HT1A Receptor Downregulation in SSRIs The chapter discusses the potential role of the 5-HT1A receptor and its downregulation in the effectiveness of SSRIs (Selective Serotonin Reuptake Inhibitors), which are commonly used antidepressants. SSRIs work by blocking the reuptake of serotonin, leading to increased serotonin levels in the brain. This alteration in serotonin levels is thought to contribute to their therapeutic effects on depression.
• 05:00 - 07:00: Role of BDNF in Depression The chapter explores the role of Brain-Derived Neurotrophic Factor (BDNF) in depression, specifically within the context of the monamine theory of depression. It highlights a key limitation of this theory, which is the delay in the antidepressant effects of medications that inhibit the reuptake of serotonin. Despite the immediate increase in neurotransmitter availability at the synaptic cleft, clinical improvements typically do not manifest until two to four weeks of continuous treatment. The chapter raises questions about the mechanisms underlying this delay and suggests a need to investigate beyond the monamine theory to fully understand these dynamics.

Mechanism of SSRIs: Monoamine Theory and the Role of BDNF Transcription

• 00:00 - 00:30 in the next slides we'll be discussing the mechanism of action of selective serotonin reuptake Inhibitors or ssris this presentation can be divided into three sections the first section is a brief overview of the monomin theory of depression and its limitations the second section discusses the effects of 5 ht1a receptor down regulation on the mechanism of action of ssris and the third section presents
• 00:30 - 01:00 recent findings on the role of bdnf in depression what does the monamine theory of depression hold this theory postulates that depression might be caused by a decrease in serotonergic and noradrenergic neurotransmission ssris are pharmacologically active at their molecular and cellular sites of action almost immediately if the reuptake of Serotonin or norepinephrine is blocked this causes
• 01:00 - 01:30 an increase in neurotransmitter availability at the synaptic Clift however here comes the fact that poses a big limitation for the monamine theory of depression anti-depressant effects are generally not seen until two to four weeks of continuous treatment so the question is how can we explain this discrepancy between immediate inhibition of Serotonin reuptake and clinical effects in the
• 01:30 - 02:00 next slides we'll explore the hypothesis that might explain the delayed therapeutic effect of anti-depressants now we will discuss the role of 5H d1a receptor down regulation in the mechanism of action of ssris we'll Begin by introducing some relevant features before starting with the effects of SSR this image shows a serotonergic neuron we can see the somatodendritic
• 02:00 - 02:30 region the axon and the preoptic terminal here is also depicted a PO synaptic neuron that is stimulated by the serotonergic neuron the next element we need to integrate for a better understanding is the 5 ht1a receptor there are 14 subtypes of Serotonin receptors the 5 ht1a is one of them when this receptor is stimulated
• 02:30 - 03:00 it inhibits firing of ser energic neurons this means that it works as an auto receptor that inhibits serotonergic activity here 58218 receptors are expressed in the somatodendritic region of a serotonergic neuron this picture is a schematic representation that emphasizes the role of 5H t1a receptors as inhibitory Auto receptors the
• 03:00 - 03:30 serotonin transporter thir is a monoamine transporter protein this is a membrane protein that transport serotonin from synaptic spaces into pre synaptic neurons selective serotonin reap take Inhibitors and other anti-depressants block the thirt transporter the result is an increased availability of serotonin in the synaptic space if we compare this image with the previous illustration showing the sendic region the difference is that
• 03:30 - 04:00 you can see an increase of Serotonin concentration this has implications in terms of regulation of 5 ht1a receptors this step is key in our explanation why here we can see the effects of increased serotonin concentrations if you pay attention there is an important difference with the previous slide there are less 5 ht1 receptors this means that 5H t1a
• 04:00 - 04:30 receptors are done regulated as a response to serotonin stimulation the serotonergic neuron reduces the number of 5 ht1a receptors this phenomenon is known as down regulation since down regulation is mediated by genomic mechanisms the reduction of 5 ht1a receptors is not immediate this occurs in weeks this has been proposed as a possible explanation of anti-depressive s delay in
• 04:30 - 05:00 therapeutic effects now we can see the effects of 5 ht1a down regulation on the serotonergic neuron here the focus is not on the somatodendritic region but on the entire neuron since there are less 5 ht1a receptors expressed in the somatodendritic region the neuron is now disinhibited as a consequence firing rate is increased this in turn increases serotonin release to the synaptic space
• 05:00 - 05:30 which stimulates post synaptic serotonin receptors in summary inhibition of Serotonin reuptake increases serotonin concentration which causes a downregulation of 5H t1a receptors after the number of 5 ht1a receptors is is reduced the neuron is disinhibited to release more serotonin in the synaptic space in the last section we'll review recent findings on
• 05:30 - 06:00 the role of bdnf in depression the neurotrophic hypothesis of depression proposes that depression is associated with reduced bdnf levels in the hyppocampus so anti-depressant treatments alleviate depressive symptoms and increase bdnf levels
• 06:00 - 06:30 this diagram shows a model that overlaps degree of impairment of neuronal plasticity with clinical severity of depression according to this paper by Lee and colleagues suicide Behavior can be a consequence of very severely impaired neuronal plasticity anti-depressant treatments promote several forms of neuronal plasticity including bdnf activity which can develop anti-depressant response it
• 06:30 - 07:00 has been proposed that neuronal plastic change can recover depressed mode